Acute Crit Care.  2024 May;39(2):294-303. 10.4266/acc.2023.01130.

Comparison of factors influencing the decision to withdraw life-sustaining treatment in intensive care unit patients after implementation of the Life-Sustaining Treatment Act in Korea

• Kim CJ
• Hong KS
• Cho S
• Park J

• KMID: 2557246
• DOI: http://doi.org/10.4266/acc.2023.01130

Abstract

Background
The decision to discontinue intensive care unit (ICU) treatment during the end-oflife stage has recently become a significant concern in Korea, with an observed increase in life-sustaining treatment (LST) withdrawal. There is a growing demand for evidence-based support for patients, families, and clinicians in making LST decisions. This study aimed to identify factors influencing LST decisions in ICU inpatients and to analyze their impact on healthcare utilization. Methods: We retrospectively reviewed medical records of ICU patients with neurological disorders, infectious disorders, or cancer who were treated at a single university hospital between January 1, 2019 and July 7, 2021. Factors influencing the decision to withdraw LST were compared between those who withdrew LST and those who did not. Results: Among 54,699 hospital admissions, LST was withdrawn in 550 cases (1%). Cancer was the most common diagnosis, followed by pneumonia and cerebral infarction. Among ICU inpatients, LST was withdrawn from 215 (withdrawal group). The withdrawal group was older (78 vs. 75 years, P=0.002), had longer total hospital stays (16 vs. 11 days, P<0.001), and higher ICU readmission rates than the control group. There were no significant differences in the healthcare costs of ICU stay between the two groups. Most LST decisions (86%) were made by family. Conclusions: The decisions to withdraw LST of ICU inpatients were influenced by age, readmission, and disease category. ICU costs were similar between the withdrawal and control groups. Further research is needed to tailor LST decisions in the ICU.

Keyword

cancer; death; healthcare cost; intensive care unit; palliative care; terminal care

Figure

• 

  Figure 1. Distribution of diseases between patients for whom life-sustaining treatment was withdrawn and the control group. Patients in the life-sustaining treatment (LST) group and control group were assigned to one of three common critical disease categories of neurological disorders, infectious disorders, and cancers. The proportion of cancer patients was significantly higher in the withdrawal group than the control group. Conversely, the numbers of patients with neurological disorders and infectious disorders were higher in the control group than the withdrawal group. ICU: intensive care unit.

• 

  Figure 2. Types of intensive care performed in the life-sustaining treatment (LST) withdrawal group (A) and control group (B) during their intensive care unit stay. The legal definition of LST includes not only cardiopulmonary resuscitation (CPR), but also mechanical ventilation, hemodialysis, vasopressors, and blood transfusion, which are commonly performed in intensive care units. The most common intensive care received during the intensive care unit stay among those who withdrew LST was, in order of frequency, mechanical ventilation, vasopressor usage, and blood transfusions. ECLS: extracorporeal life support.

• 

  Figure 3. Identity of decision-makers to withdraw life-sustaining treatment among intensive care unit inpatients. Overall, withdrawal of life-sustaining treatment was predominantly by family determination, but it varied by the nature of the disease: self-determination was higher for cancer patients compared to other diseases and lower for neurological disorders with altered consciousness and sepsis with the possibility of rapid deterioration.

Reference

1. Welfare Ministry of Health and Welfare. Act on decisions on life-sustaining treatment for patients in hospice and palliative care or at the end of life. No. 17218. Welfare Ministry of Health and Welfare;2020.

2. Kim HA, Cho M, Son DS. Temporal change in the use of laboratory and imaging tests in one week before death, 2006-2015. J Korean Med Sci. 2023; 38:e98.

3. Council on Ethical and Judician Affairs, American Medical Association. Medical futility in end-of-life care: report of the council on ethical and judicial affairs. JAMA. 1999; 281:937–41.

4. Curtis JR, Vincent JL. Ethics and end-of-life care for adults in the intensive care unit. Lancet. 2010; 376:1347–53.

5. Lee SI, Hong KS, Park J, Lee YJ. Decision-making regarding withdrawal of life-sustaining treatment and the role of intensivists in the intensive care unit: a single-center study. Acute Crit Care. 2020; 35:179–88.

6. Park SY, Lee B, Seon JY, Oh IH. A national study of life-sustaining treatments in South Korea: what factors affect decision-making? Cancer Res Treat. 2021; 53:593–600.

7. Kim JS, Yoo SH, Choi W, Kim Y, Hong J, Kim MS, et al. Implication of the life-sustaining treatment decisions act on end-of-life care for Korean terminal patients. Cancer Res Treat. 2020; 52:917–24.

8. Phua J, Joynt GM, Nishimura M, Deng Y, Myatra SN, Chan YH, et al. Withholding and withdrawal of life-sustaining treatments in intensive care units in Asia. JAMA Intern Med. 2015; 175:363–71.

9. Yun YH, Lee CG, Kim SY, Lee SW, Heo DS, Kim JS, Lee KS, Hong YS, et al. The attitudes of cancer patients and their families toward the disclosure of terminal illness. J Clin Oncol. 2004; 22:307–14.

10. Manalo MF. End-of-life decisions about withholding or withdrawing therapy: medical, ethical, and religio-cultural considerations. Palliat Care. 2013; 7:1–5.

11. Kim H, Im HS, Lee KO, Min YJ, Jo JC, Choi Y, et al. Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act. BMC Palliat Care. 2021; 20:63.

12. Luce JM. End-of-life decision making in the intensive care unit. Am J Respir Crit Care Med. 2010; 182:6–11.

13. Yildirim S, Durmaz Y, Şan Y, Taşkıran İ, Cinleti BA, Kirakli C. Cost of chronic critically ill patients to the healthcare system: a single-center experience from a developing country. Indian J Crit Care Med. 2021; 25:519–23.

14. Khandelwal N, Benkeser D, Coe NB, Engelberg RA, Teno JM, Curtis JR. Patterns of cost for patients dying in the intensive care unit and implications for cost savings of palliative care interventions. J Palliat Med. 2016; 19:1171–8.

15. Slatyer MA, James OF, Moore PG, Leeder SR. Costs, severity of illness and outcome in intensive care. Anaesth Intensive Care. 1986; 14:381–9.

16. Kim D, Yoo SH, Seo S, Lee HJ, Kim MS, Shin SJ, et al. Analysis of cancer patient decision-making and health service utilization after enforcement of the life-sustaining treatment decision-making act in Korea. Cancer Res Treat. 2022; 54:20–9.

17. Arabi YM, Myatra SN, Lobo SM. Surging ICU during COVID-19 pandemic: an overview. Curr Opin Crit Care. 2022; 28:638–44.

18. Lautrette A, Darmon M, Megarbane B, Joly LM, Chevret S, Adrie C, et al. A communication strategy and brochure for relatives of patients dying in the ICU. N Engl J Med. 2007; 356:469–78.

19. Ursin LØ. Withholding and withdrawing life-sustaining treatment: ethically equivalent? Am J Bioeth. 2019; 19:10–20.

20. Jeong W, Kim S, Kim H, Park EC, Jang SI. Effects of life-sustaining treatment plans on healthcare expenditure and healthcare utilization. BMC Health Serv Res. 2023; 23:1236.